Non-small cell lung cancer (NSCLC) is one of the leading causes of death in Western countries. Today, a new frontier in the fight against cancer is immunotherapy, a treatment that aims to "awaken" the patient's immune system to help it recognize and attack cancer cells.
Among the various approaches, there is significant focus on therapies that activate T lymphocytes, a type of immune cell, encouraging them to react against the tumor. These treatments have led to important progress and represent a hope for the future.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Histologically or cytologically confirmed diagnosis of NSCLC
* Possibility to obtain blood samples
* Patient candidate, in any therapy line, for a therapy with any checkpoint inhibitor including single agent pembrolizumab, single agent atezolizumab, single agent nivolumab, single agent durvalumab or combination of nivolumab and ipilimumab
* Performance status 0-2 (ECOG)
* Patient compliance to trial procedures
* Age ≥ 18 years
* Written informed consent
Exclusion Criteria:
* No possibility to obtain blood samples
* Previous therapy with any checkpoint inhibitor
* Patient candidate for a therapy with a checkpoint inhibitor in combination with chemotherapy or any other non-checkpoint inhibitors
* Pregnancy or lactating
Primary outcome measure(s)
Detection of Anti-Checkpoint Inhibitor Antibodies in Plasma of Participants Receiving Treatment — From the start of treatment until the first documented progression, completion of treatment cycles, or death from any cause, whichever occurs first, assessed from the start of treatment up to 12 months. Detection of anti-checkpoint inhibitors antibodies in plasma
Trial sites (2)
Facility
City
Region
Status
Istituto Tumori Regina Elena
Roma
RM
Enrolling By Invitation
Istituto Tumori Regina Elena
Roma
RM
Recruiting
More Fondazione Ricerca Traslazionale trials in Italy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
